

Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies. ^[1]

Enviado por [Mariano Garcia-Blanco](#) ^[2] el 9 octubre 2012 - 5:49pm



^[2]

Título	Reprogramming of tau alternative splicing by spliceosome-mediated RNA trans-splicing: implications for tauopathies.
Publication Type	Journal Article
Year of Publication	2005
Autores	Rodriguez-Martin, T ^[3] , García-Blanco, MA ^[4] , Mansfield, GS ^[5] , Grover, AC ^[6] , Hutton, M ^[7] , Yu, Q ^[8] , Zhou, J ^[9] , Anderton, BH ^[10] , Gallo, J-M ^[11]
Journal	Proc Natl Acad Sci U S A
Volume	102
Issue	43
Pagination	15659-64
Date Published	2005 Oct 25
ISSN	0027-8424
Palabras clave	Alternative Splicing ^[12] , Animals ^[13] , Base Sequence ^[14] , Cell Line ^[15] , Cercopithecus aethiops ^[16] , COS Cells ^[17] , Exons ^[18] , Humans ^[19] , Molecular Sequence Data ^[20] , Neuroblastoma ^[21] , Spliceosomes ^[22] , tau Proteins ^[23] , Tauopathies ^[24] , Trans-Splicing ^[25]

Abstract

Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is caused by mutations in the gene encoding the microtubule-associated protein, tau. Some FTDP-17 mutations affect exon 10 splicing. To correct aberrant exon 10 splicing while retaining endogenous transcriptional control, we evaluated the feasibility of using spliceosome-mediated RNA trans-splicing (SMaRT) to reprogram tau mRNA. We designed a pre-trans-splicing molecule containing human tau exons 10 to 13 and a binding domain complementary to the 3' end of tau intron 9. A minigene comprising tau exons 9, 10, and 11 and minimal flanking intronic sequences was used as a target. RT-PCR analysis of SH-SY5Y cells or COS cells cotransfected with a minigene and a pre-trans-splicing molecule using primers to opposite sides of the predicted splice junction generated products containing exons 9 to 13. Sequencing of the chimeric products showed that an exact exon 9-exon 10 junction had been created, thus demonstrating that tau RNA can be reprogrammed by trans-splicing. Furthermore, by using the same paradigm with a minigene containing full-length intronic sequences, we show that cis-splicing exclusion of exon 10 can be by-passed by trans-splicing and that conversion of exon 10(-) tau RNA into exon 10(+) tau RNA could be achieved with approximately 34% efficiency. Our results demonstrate that an alternatively spliced exon can be replaced by trans-splicing and open the way to novel therapeutic applications of SMaRT for tauopathies and other disorders linked to aberrant alternative splicing.

DOI [10.1073/pnas.0503150102](https://doi.org/10.1073/pnas.0503150102) [26]

Alternate Journal Proc. Natl. Acad. Sci. U.S.A.

PubMed ID [16230627](https://pubmed.ncbi.nlm.nih.gov/16230627/) [27]

Copyright © 2006-Presente CienciaPR y CAPRI, excepto donde sea indicado lo contrario, todos los derechos reservados

[Privacidad](#) | [Términos](#) | [Normas de la Comunidad](#) | [Sobre CienciaPR](#) | [Contáctenos](#)

Source URL: <https://www.cienciapr.org/es/reprogramming-tau-alternative-splicing-spliceosome-mediated-rna-trans-splicing-implications?language=en>

Links

[1] <https://www.cienciapr.org/es/reprogramming-tau-alternative-splicing-spliceosome-mediated-rna-trans-splicing-implications?language=en> [2] <https://www.cienciapr.org/es/user/garci001?language=en> [3] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=603> [4] <https://www.cienciapr.org/es/user/13/biblio?language=en> [5] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=605> [6] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=684> [7] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=685> [8] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=686> [9] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=687> [10] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=606> [11] <https://www.cienciapr.org/es/biblio?language=en&f%5Bauthor%5D=607> [12]

<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=746> [13]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=1> [14]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=2> [15]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=335> [16]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=79> [17]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=75> [18]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=751> [19]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=9> [20]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=104> [21]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=890> [22]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=802> [23]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=805> [24]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=803> [25]
<https://www.cienciapr.org/es/biblio?language=en&f%5Bkeyword%5D=804> [26]
<http://dx.doi.org/10.1073/pnas.0503150102> [27]
<https://www.ncbi.nlm.nih.gov/pubmed/16230627?dopt=Abstract>